{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:54:00Z","timestamp":1787583240626,"version":"build-2736575974"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00520-023-08299-w","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T04:43:05Z","timestamp":1704948185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advances in the treatment of malignant ascites in China"],"prefix":"10.1007","volume":"32","author":[{"given":"Junzi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxue","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuguang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"8299_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00001888-194101000-00024","volume":"16","author":"&Na","year":"1941","unstructured":"&Na (1941) Taber??s Cyclopedic Medical Dictionary. Acad Med 16:63. https:\/\/doi.org\/10.1097\/00001888-194101000-00024","journal-title":"Acad Med"},{"key":"8299_CR2","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdl499","volume":"18","author":"AA Ayantunde","year":"2007","unstructured":"Ayantunde AA, Parsons SL (2007) Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 18:945\u2013949. https:\/\/doi.org\/10.1093\/annonc\/mdl499","journal-title":"Ann Oncol"},{"key":"8299_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.4103\/0256-4947.55167","volume":"29","author":"MW Saif","year":"2009","unstructured":"Saif MW, Siddiqui IAP, Sohail MA (2009) Management of ascites due to gastrointestinal malignancy. Ann Saudi Med 29:369\u2013377. https:\/\/doi.org\/10.4103\/0256-4947.55167","journal-title":"Ann Saudi Med"},{"key":"8299_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","volume":"42","author":"G Becker","year":"2006","unstructured":"Becker G, Galandi D, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42:589\u2013597. https:\/\/doi.org\/10.1016\/j.ejca.2005.11.018","journal-title":"Eur J Cancer"},{"key":"8299_CR5","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1089\/jpm.2018.0595","volume":"22","author":"T Hisanaga","year":"2019","unstructured":"Hisanaga T, Shinjo T, Imai K et al (2019) Clinical Guidelines for Management of Gastrointestinal Symptoms in Cancer Patients: The Japanese Society of Palliative Medicine Recommendations. J Palliat Med 22:986\u2013997. https:\/\/doi.org\/10.1089\/jpm.2018.0595","journal-title":"J Palliat Med"},{"key":"8299_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0885-3924(98)00037-2","volume":"16","author":"CW Lee","year":"1998","unstructured":"Lee CW, Bociek G, Faught W (1998) A survey of practice in management of malignant ascites. J Pain Symptom Manag 16:96\u2013101. https:\/\/doi.org\/10.1016\/S0885-3924(98)00037-2","journal-title":"J Pain Symptom Manag"},{"key":"8299_CR7","doi-asserted-by":"publisher","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. JCO 32:1302\u20131308. https:\/\/doi.org\/10.1200\/JCO.2013.51.4489","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"8299_CR8","doi-asserted-by":"publisher","unstructured":"Abd El Aziz MA (2019) Productive cross-talk with the microenvironment: a critical step in ovarian cancer metastasis. Cancers 11. https:\/\/doi.org\/10.3390\/cancers11101608","DOI":"10.3390\/cancers11101608"},{"key":"8299_CR9","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3390\/cells9051299","volume":"9","author":"M Nowak","year":"2020","unstructured":"Nowak M, Klink M (2020) The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer. Cells 9:1299. https:\/\/doi.org\/10.3390\/cells9051299","journal-title":"Cells"},{"key":"8299_CR10","doi-asserted-by":"publisher","first-page":"e000875","DOI":"10.1136\/jitc-2020-000875","volume":"8","author":"SF Adams","year":"2020","unstructured":"Adams SF, Grimm AJ, Chiang CL-L et al (2020) Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. J Immunother Cancer 8:e000875. https:\/\/doi.org\/10.1136\/jitc-2020-000875","journal-title":"J Immunother Cancer"},{"key":"8299_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0304-3835(92)90186-Y","volume":"62","author":"B Sheid","year":"1992","unstructured":"Sheid B (1992) Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. Cancer Lett 62:153\u2013158. https:\/\/doi.org\/10.1016\/0304-3835(92)90186-Y","journal-title":"Cancer Lett"},{"key":"8299_CR12","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.3390\/ijms23116215","volume":"23","author":"M Rakina","year":"2022","unstructured":"Rakina M, Kazakova A, Villert A, Kolomiets L, Larionova I (2022) Spheroid formation and peritoneal metastasis in ovarian cancer: the role of stromal and immune components. Int J Mol Sci 23:6215. https:\/\/doi.org\/10.3390\/ijms23116215","journal-title":"Int J Mol Sci"},{"key":"8299_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1053\/j.sempedsurg.2014.06.002","volume":"23","author":"SC Blackburn","year":"2014","unstructured":"Blackburn SC, Stanton MP (2014) Anatomy and physiology of the peritoneum. Semin Pediatr Surg 23:326\u2013330. https:\/\/doi.org\/10.1053\/j.sempedsurg.2014.06.002","journal-title":"Semin Pediatr Surg"},{"key":"8299_CR14","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.fertnstert.2016.09.005","volume":"106","author":"SE Mutsaers","year":"2016","unstructured":"Mutsaers SE, Pr\u00eale CM-A, Pengelly S, Herrick SE (2016) Mesothelial cells and peritoneal homeostasis. Fertil Steril 106:1018\u20131024. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.09.005","journal-title":"Fertil Steril"},{"key":"8299_CR15","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/apt.14284","volume":"46","author":"B Lizaola","year":"2017","unstructured":"Lizaola B, Bonder A, Trivedi HD, Tapper EB, Cardenas A (2017) Review article: the diagnostic approach and current management of chylous ascites. Aliment Pharmacol Ther 46:816\u2013824. https:\/\/doi.org\/10.1111\/apt.14284","journal-title":"Aliment Pharmacol Ther"},{"key":"8299_CR16","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3390\/cancers13174318","volume":"13","author":"BP Rickard","year":"2021","unstructured":"Rickard BP, Conrad C, Sorrin AJ et al (2021) Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers (Basel) 13:4318. https:\/\/doi.org\/10.3390\/cancers13174318","journal-title":"Cancers (Basel)"},{"key":"8299_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K (2020) The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer 123:9\u201316. https:\/\/doi.org\/10.1038\/s41416-020-0875-x","journal-title":"Br J Cancer"},{"key":"8299_CR18","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","volume":"198","author":"RA Adam","year":"2004","unstructured":"Adam RA, Adam YG (2004) Malignant ascites: past, present, and future. J Am Coll Surg 198:999\u20131011. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2004.01.035","journal-title":"J Am Coll Surg"},{"key":"8299_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nrc1611","volume":"5","author":"H Naora","year":"2005","unstructured":"Naora H, Montell DJ (2005) Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5:355\u2013366. https:\/\/doi.org\/10.1038\/nrc1611","journal-title":"Nat Rev Cancer"},{"key":"8299_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10434-999-0373-0","volume":"6","author":"BK Zebrowski","year":"1999","unstructured":"Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM (1999) Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6:373\u2013378. https:\/\/doi.org\/10.1007\/s10434-999-0373-0","journal-title":"Ann Surg Oncol"},{"key":"8299_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","volume":"18","author":"E Cavazzoni","year":"2013","unstructured":"Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A (2013) Malignant ascites: pathophysiology and treatment. Int J Clin Oncol 18:1\u20139. https:\/\/doi.org\/10.1007\/s10147-012-0396-6","journal-title":"Int J Clin Oncol"},{"key":"8299_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DSP, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13:273\u2013282. https:\/\/doi.org\/10.1038\/nrc3432","journal-title":"Nat Rev Cancer"},{"key":"8299_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0065-2571(94)00022-U","volume":"35","author":"PD Brown","year":"1995","unstructured":"Brown PD (1995) Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzym Regul 35:293\u2013301. https:\/\/doi.org\/10.1016\/0065-2571(94)00022-U","journal-title":"Adv Enzym Regul"},{"key":"8299_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.tice.2016.11.004","volume":"49","author":"JOAM van Baal","year":"2017","unstructured":"van Baal JOAM, Van de Vijver KK, Nieuwland R et al (2017) The histophysiology and pathophysiology of the peritoneum. Tissue Cell 49:95\u2013105. https:\/\/doi.org\/10.1016\/j.tice.2016.11.004","journal-title":"Tissue Cell"},{"key":"8299_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cncy.20071","volume":"118","author":"F Hasteh","year":"2010","unstructured":"Hasteh F, Lin GY, Weidner N, Michael CW (2010) The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol 118:90\u201396. https:\/\/doi.org\/10.1002\/cncy.20071","journal-title":"Cancer Cytopathol"},{"key":"8299_CR26","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.21873\/anticanres.13800","volume":"39","author":"A Coosemans","year":"2019","unstructured":"Coosemans A, Baert T, D\u2019Heygere V et al (2019) Increased immunosuppression is related to increased amounts of ascites and inferior prognosis in ovarian cancer. Anticancer Res 39:5953\u20135962. https:\/\/doi.org\/10.21873\/anticanres.13800","journal-title":"Anticancer Res"},{"key":"8299_CR27","doi-asserted-by":"publisher","first-page":"367103","DOI":"10.1155\/2014\/367103","volume":"2014","author":"T Feigenberg","year":"2014","unstructured":"Feigenberg T, Clarke B, Virtanen C et al (2014) Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Biomed Res Int 2014:367103. https:\/\/doi.org\/10.1155\/2014\/367103","journal-title":"Biomed Res Int"},{"key":"8299_CR28","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.3390\/ijms23084383","volume":"23","author":"K Uno","year":"2022","unstructured":"Uno K, Iyoshi S, Yoshihara M et al (2022) Metastatic voyage of ovarian cancer cells in ascites with the assistance of various cellular components. Int J Mol Sci 23:4383. https:\/\/doi.org\/10.3390\/ijms23084383","journal-title":"Int J Mol Sci"},{"key":"8299_CR29","unstructured":"2019 JSPM\u4e34\u5e8a\u6307\u5357:\u764c\u75c7\u60a3\u8005\u80c3\u80a0\u9053\u75c7\u72b6\u7684\u7ba1\u7406\u5efa\u8bae. https:\/\/guide.medlive.cn\/guideline\/17812. Accessed 7 Mar 2023"},{"key":"8299_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-021-02077-6","volume":"27","author":"K Matsusaki","year":"2022","unstructured":"Matsusaki K, Aridome K, Emoto S et al (2022) Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021). Int J Clin Oncol 27:1\u20136. https:\/\/doi.org\/10.1007\/s10147-021-02077-6","journal-title":"Int J Clin Oncol"},{"key":"8299_CR31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12885-022-09336-3","volume":"22","author":"N Yokomichi","year":"2022","unstructured":"Yokomichi N, Imai K, Sakamoto M et al (2022) Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites. BMC Cancer 22:218. https:\/\/doi.org\/10.1186\/s12885-022-09336-3","journal-title":"BMC Cancer"},{"key":"8299_CR32","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/0016-5085(92)91520-e","volume":"103","author":"PJ Pockros","year":"1992","unstructured":"Pockros PJ, Esrason KT, Nguyen C, Duque J, Woods S (1992) Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 103:1302\u20131306. https:\/\/doi.org\/10.1016\/0016-5085(92)91520-e","journal-title":"Gastroenterology"},{"key":"8299_CR33","first-page":"474","volume":"6","author":"JR Mackey","year":"1996","unstructured":"Mackey JR, Venner PM (1996) Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol 6:474\u2013480","journal-title":"Can J Oncol"},{"key":"8299_CR34","doi-asserted-by":"publisher","first-page":"10936","DOI":"10.3748\/wjg.v21.i39.10936","volume":"21","author":"H Maeda","year":"2015","unstructured":"Maeda H, Kobayashi M, Sakamoto J (2015) Evaluation and treatment of malignant ascites secondary to gastric cancer. World J Gastroenterol 21:10936\u201310947. https:\/\/doi.org\/10.3748\/wjg.v21.i39.10936","journal-title":"World J Gastroenterol"},{"key":"8299_CR35","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3748\/wjg.v12.i9.1412","volume":"12","author":"M Kobayashi","year":"2006","unstructured":"Kobayashi M (2006) Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. WJG 12:1412. https:\/\/doi.org\/10.3748\/wjg.v12.i9.1412","journal-title":"WJG"},{"key":"8299_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00280-012-2066-9","volume":"71","author":"H Tamegai","year":"2013","unstructured":"Tamegai H, Kaiga T, Kochi M et al (2013) Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites. Cancer Chemother Pharmacol 71:727\u2013731. https:\/\/doi.org\/10.1007\/s00280-012-2066-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"8299_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.critrevonc.2007.12.001","volume":"66","author":"K Abbrederis","year":"2008","unstructured":"Abbrederis K, Lorenzen S, von Weikersthal LF, Vehling-Kaiser U, Schuster T, Rothling N, Peschel C, Lordick F (2008) Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. Crit Rev Oncol Hematol 66:84\u201390. https:\/\/doi.org\/10.1016\/j.critrevonc.2007.12.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"8299_CR38","first-page":"2259","volume":"40","author":"K Nishikawa","year":"2013","unstructured":"Nishikawa K, Iwase K, Aono T et al (2013) A case of paclitaxel-resistant recurrent gastric cancer responsive to S-1 plus docetaxel. Gan To Kagaku Ryoho 40:2259\u20132261","journal-title":"Gan To Kagaku Ryoho"},{"key":"8299_CR39","first-page":"643","volume":"38","author":"Y Kimura","year":"2011","unstructured":"Kimura Y, Imasato M, Yano H et al (2011) Paclitaxel-resistant recurrent gastric cancer responsive to docetaxel: a case report. Gan To Kagaku Ryoho 38:643\u2013645","journal-title":"Gan To Kagaku Ryoho"},{"key":"8299_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/jjco\/hys111","volume":"42","author":"S Iwasa","year":"2012","unstructured":"Iwasa S, Goto M, Yasui H et al (2012) Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake. Jpn J Clin Oncol 42:787\u2013793. https:\/\/doi.org\/10.1093\/jjco\/hys111","journal-title":"Jpn J Clin Oncol"},{"key":"8299_CR41","volume-title":"Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites","author":"I Takeyoshi","year":"2011","unstructured":"Takeyoshi I, Makita F, Iwazaki S et al (2011) Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites. Anticancer Research"},{"key":"8299_CR42","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/jjco\/hym131","volume":"37","author":"SY Oh","year":"2007","unstructured":"Oh SY, Kwon H-C, Lee S et al (2007) A phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 37:930\u2013935. https:\/\/doi.org\/10.1093\/jjco\/hym131","journal-title":"Jpn J Clin Oncol"},{"key":"8299_CR43","unstructured":"Treatment of hairy cell leukemia with recombinant alpha-interferon - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/3730612\/. Accessed 8 Mar 2023"},{"key":"8299_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1521-6926(02)00084-1","volume":"16","author":"S Ahmed","year":"2003","unstructured":"Ahmed S, Rai KR (2003) Interferon in the treatment of hairy-cell leukemia. Best Pract Res Clin Haematol 16:69\u201381. https:\/\/doi.org\/10.1016\/S1521-6926(02)00084-1","journal-title":"Best Pract Res Clin Haematol"},{"key":"8299_CR45","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA (2014) IL-2: the first effective immunotherapy for human cancer. J Immunol 192:5451\u20135458. https:\/\/doi.org\/10.4049\/jimmunol.1490019","journal-title":"J Immunol"},{"key":"8299_CR46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ (2019) Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov 18:175\u2013196. https:\/\/doi.org\/10.1038\/s41573-018-0006-z","journal-title":"Nat Rev Drug Discov"},{"key":"8299_CR47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13048-016-0236-9","volume":"9","author":"G Mittica","year":"2016","unstructured":"Mittica G, Capellero S, Genta S, Cagnazzo C, Aglietta M, Sangiolo D, Valabrega G (2016) Adoptive immunotherapy against ovarian cancer. J Ovarian Res 9:30. https:\/\/doi.org\/10.1186\/s13048-016-0236-9","journal-title":"J Ovarian Res"},{"key":"8299_CR48","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/0090-8258(89)90101-7","volume":"34","author":"M Kamada","year":"1989","unstructured":"Kamada M, Sakamoto Y, Furumoto H et al (1989) Treatment of malignant ascites with allogeneic and autologous lymphokine-activated killer cells. Gynecol Oncol 34:34\u201337. https:\/\/doi.org\/10.1016\/0090-8258(89)90101-7","journal-title":"Gynecol Oncol"},{"key":"8299_CR49","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/jnci\/81.8.602","volume":"81","author":"WJ Urba","year":"1989","unstructured":"Urba WJ, Clark JW, Steis RG et al (1989) Intraperitoneal lymphokine-activated killer cell\/interleukin-2 therapy in patients with intra- abdominal cancer: immunologic considerations. JNCI: J Nat Cancer Instit 81:602\u2013611. https:\/\/doi.org\/10.1093\/jnci\/81.8.602","journal-title":"JNCI: J Nat Cancer Instit"},{"key":"8299_CR50","doi-asserted-by":"publisher","unstructured":"Steis RG, Urba WJ, VanderMolen LA, et al (1990) Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. JCO 8:1618\u20131629. https:\/\/doi.org\/10.1200\/JCO.1990.8.10.1618","DOI":"10.1200\/JCO.1990.8.10.1618"},{"key":"8299_CR51","first-page":"6302","volume":"50","author":"JA Stewart","year":"1990","unstructured":"Stewart JA, Belinson JL, Moore AL et al (1990) Phase I trial of intraperitoneal recombinant interleukin-2\/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 50:6302\u20136310","journal-title":"Cancer Res"},{"key":"8299_CR52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139\u2013149. https:\/\/doi.org\/10.1084\/jem.174.1.139","journal-title":"J Exp Med"},{"key":"8299_CR53","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/BF02977372","volume":"30","author":"HM Kim","year":"2007","unstructured":"Kim HM, Kang JS, Lim J et al (2007) Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch Pharm Res 30:1464\u20131470. https:\/\/doi.org\/10.1007\/BF02977372","journal-title":"Arch Pharm Res"},{"key":"8299_CR54","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/CJI.0000000000000021","volume":"37","author":"J Liu","year":"2014","unstructured":"Liu J, Li H, Cao S et al (2014) Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment. J Immunother 37:115\u2013122. https:\/\/doi.org\/10.1097\/CJI.0000000000000021","journal-title":"J Immunother"},{"key":"8299_CR55","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","volume":"139","author":"S Pesce","year":"2017","unstructured":"Pesce S, Greppi M, Tabellini G et al (2017) Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol 139:335\u2013346.e3. https:\/\/doi.org\/10.1016\/j.jaci.2016.04.025","journal-title":"J Allergy Clin Immunol"},{"key":"8299_CR56","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/ijms20040890","volume":"20","author":"M Greppi","year":"2019","unstructured":"Greppi M, Tabellini G, Patrizi O et al (2019) Strengthening the antitumor NK cell function for the treatment of ovarian cancer. IJMS 20:890. https:\/\/doi.org\/10.3390\/ijms20040890","journal-title":"IJMS"},{"key":"8299_CR57","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH (2017) The principles of engineering immune cells to treat cancer. Cell 168:724\u2013740. https:\/\/doi.org\/10.1016\/j.cell.2017.01.016","journal-title":"Cell"},{"key":"8299_CR58","doi-asserted-by":"publisher","unstructured":"Imai Y, Hasegawa K, Matsushita H, Fujieda N, Sato S, Miyagi E, Kakimi K, Fujiwara K (2018) Expression of multiple immune checkpoint molecules on T\u00ef\u00bf\u00bdcells in malignant ascites from epithelial ovarian carcinoma. Oncol Lett. https:\/\/doi.org\/10.3892\/ol.2018.8101","DOI":"10.3892\/ol.2018.8101"},{"key":"8299_CR59","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","volume":"19","author":"K Abiko","year":"2013","unstructured":"Abiko K, Mandai M, Hamanishi J et al (2013) PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 19:1363\u20131374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2199","journal-title":"Clin Cancer Res"},{"key":"8299_CR60","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann J, Sch\u00fc\u00dfler-Lenz M, Bondanza A, Buchholz CJ (2017) Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med 9:1183\u20131197. https:\/\/doi.org\/10.15252\/emmm.201607485","journal-title":"EMBO Mol Med"},{"key":"8299_CR61","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA et al (2016) Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44:380\u2013390. https:\/\/doi.org\/10.1016\/j.immuni.2016.01.021","journal-title":"Immunity"},{"key":"8299_CR62","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/vaccines6030054","volume":"6","author":"A Thadi","year":"2018","unstructured":"Thadi A, Khalili M, Morano W, Richard S, Katz S, Bowne W (2018) Early investigations and recent advances in intraperitoneal immunotherapy for peritoneal metastasis. Vaccines 6:54. https:\/\/doi.org\/10.3390\/vaccines6030054","journal-title":"Vaccines"},{"key":"8299_CR63","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","volume":"21","author":"SC Katz","year":"2015","unstructured":"Katz SC, Burga RA, McCormack E et al (2015) Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor\u2013modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res 21:3149\u20133159. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1421","journal-title":"Clin Cancer Res"},{"key":"8299_CR64","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","volume":"71","author":"D-G Song","year":"2011","unstructured":"Song D-G, Ye Q, Carpenito C et al (2011) In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 71:4617\u20134627. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0422","journal-title":"Cancer Res"},{"key":"8299_CR65","first-page":"106","volume":"8","author":"Y Han","year":"2018","unstructured":"Han Y, Liu C, Li G et al (2018) Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. Am J Cancer Res 8:106\u2013119","journal-title":"Am J Cancer Res"},{"key":"8299_CR66","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4161\/mabs.2.3.11791","volume":"2","author":"D Chelius","year":"2010","unstructured":"Chelius D, Ruf P, Gruber P et al (2010) Structural and functional characterization of the trifunctional antibody catumaxomab. MABS 2:309\u2013319. https:\/\/doi.org\/10.4161\/mabs.2.3.11791","journal-title":"MABS"},{"key":"8299_CR67","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","volume":"13","author":"A Burges","year":"2007","unstructured":"Burges A, Wimberger P, K\u00fcmper C et al (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM \u00d7 anti-CD3 antibody: a phase I\/II study. Clin Cancer Res 13:3899\u20133905. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2769","journal-title":"Clin Cancer Res"},{"key":"8299_CR68","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/annonc\/mds178","volume":"23","author":"P Wimberger","year":"2012","unstructured":"Wimberger P, Gilet H, Gonschior A-K et al (2012) Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II\/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol 23:1979\u20131985. https:\/\/doi.org\/10.1093\/annonc\/mds178","journal-title":"Ann Oncol"},{"key":"8299_CR69","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1471-2407-14-148","volume":"14","author":"D Go\u00e9r\u00e9","year":"2014","unstructured":"Go\u00e9r\u00e9 D, Gras-Chaput N, Aup\u00e9rin A, Flament C, Mariette C, Glehen O, Zitvogel L, Elias D (2014) Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer 14:148. https:\/\/doi.org\/10.1186\/1471-2407-14-148","journal-title":"BMC Cancer"},{"key":"8299_CR70","doi-asserted-by":"publisher","first-page":"28059","DOI":"10.18632\/oncotarget.8574","volume":"7","author":"J Borlak","year":"2016","unstructured":"Borlak J, L\u00e4nger F, Spanel R, Sch\u00f6ndorfer G, Dittrich C (2016) Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fc\u03b3 receptors. Oncotarget 7:28059\u201328074. https:\/\/doi.org\/10.18632\/oncotarget.8574","journal-title":"Oncotarget"},{"key":"8299_CR71","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00280-015-2728-5","volume":"75","author":"M Mau-S\u00f8rensen","year":"2015","unstructured":"Mau-S\u00f8rensen M, Dittrich C, Dienstmann R, Lassen U, B\u00fcchler W, Martinius H, Tabernero J (2015) A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Cancer Chemother Pharmacol 75:1065\u20131073. https:\/\/doi.org\/10.1007\/s00280-015-2728-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"8299_CR72","unstructured":"Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/14760091\/. Accessed 7 Mar 2023"},{"key":"8299_CR73","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2217\/fon.09.35","volume":"5","author":"JW Moroney","year":"2009","unstructured":"Moroney JW, Sood AK, Coleman RL (2009) Aflibercept in epithelial ovarian carcinoma. Future Oncol 5:591\u2013600. https:\/\/doi.org\/10.2217\/fon.09.35","journal-title":"Future Oncol"},{"key":"8299_CR74","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S1726-4901(10)70097-6","volume":"73","author":"L-S Teng","year":"2010","unstructured":"Teng L-S, Jin K-T, He K-F, Zhang J, Wang H-H, Cao J (2010) Clinical applications of VEGF-Trap (Aflibercept) in cancer treatment. J Chin Med Assoc 73:449\u2013456. https:\/\/doi.org\/10.1016\/S1726-4901(10)70097-6","journal-title":"J Chin Med Assoc"},{"key":"8299_CR75","first-page":"5721","volume":"9","author":"AT Byrne","year":"2003","unstructured":"Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB (2003) Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9:5721\u20135728","journal-title":"Clin Cancer Res"},{"key":"8299_CR76","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592\u2013603. https:\/\/doi.org\/10.1038\/nrc2442","journal-title":"Nat Rev Cancer"},{"key":"8299_CR77","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/cancers10080266","volume":"10","author":"N Nwani","year":"2018","unstructured":"Nwani N, Sima L, Nieves-Neira W, Matei D (2018) Targeting the microenvironment in high grade serous ovarian cancer. Cancers 10:266. https:\/\/doi.org\/10.3390\/cancers10080266","journal-title":"Cancers"},{"key":"8299_CR78","first-page":"4272","volume":"7","author":"Y-Q Ai","year":"2014","unstructured":"Ai Y-Q, Cai K, Hu J-H, Jiang L-W, Gao Y-R, Zhao H, Jia S-C (2014) The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites. Int J Clin Exp Med 7:4272\u20134281","journal-title":"Int J Clin Exp Med"},{"key":"8299_CR79","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","volume":"4","author":"SL Sangisetty","year":"2012","unstructured":"Sangisetty SL (2012) Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. WJGS 4:87. https:\/\/doi.org\/10.4240\/wjgs.v4.i4.87","journal-title":"WJGS"},{"key":"8299_CR80","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1007\/s00520-014-2557-9","volume":"23","author":"CF Jehn","year":"2015","unstructured":"Jehn CF, K\u00fcpferling S, Oskay-\u00d6zcelik G, L\u00fcftner D (2015) A survey of treatment approaches of malignant ascites in Germany and Austria. Support Care Cancer 23:2073\u20132078. https:\/\/doi.org\/10.1007\/s00520-014-2557-9","journal-title":"Support Care Cancer"},{"key":"8299_CR81","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/s0002-9610(06)80078-4","volume":"159","author":"DW Weaver","year":"1990","unstructured":"Weaver DW, Wiencek RG, Bouwman DL (1990) Percutaneous Denver peritoneovenous shunt insertion. Am J Surg 159:600\u2013601. https:\/\/doi.org\/10.1016\/s0002-9610(06)80078-4","journal-title":"Am J Surg"},{"key":"8299_CR82","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00270-010-0057-y","volume":"34","author":"S Sugawara","year":"2011","unstructured":"Sugawara S, Sone M, Arai Y et al (2011) Radiological insertion of denver peritoneovenous shunts for malignant refractory ascites: a retrospective multicenter study (JIVROSG-0809). Cardiovasc Intervent Radiol 34:980\u2013988. https:\/\/doi.org\/10.1007\/s00270-010-0057-y","journal-title":"Cardiovasc Intervent Radiol"},{"key":"8299_CR83","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/BF02303809","volume":"1","author":"DL Schumacher","year":"1994","unstructured":"Schumacher DL, Saclarides TJ, Staren ED (1994) Peritoneovenous shunts for palliation of the patient with malignant ascites. Ann Surg Oncol 1:378\u2013381. https:\/\/doi.org\/10.1007\/BF02303809","journal-title":"Ann Surg Oncol"},{"key":"8299_CR84","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/1097-0142(20010401)91:7<1247::AID-CNCR1125>3.0.CO;2-W","volume":"91","author":"SC Bieligk","year":"2001","unstructured":"Bieligk SC, Calvo BF, Coit DG (2001) Peritoneovenous shunting for nongynecologic malignant ascites. Cancer 91:1247\u20131255","journal-title":"Cancer"},{"key":"8299_CR85","first-page":"794","volume":"48","author":"RH Hu","year":"2001","unstructured":"Hu RH, Lee PH (2001) Salvaging procedures for dysfunctional peritoneovenous shunt. Hepatogastroenterology 48:794\u2013797","journal-title":"Hepatogastroenterology"},{"key":"8299_CR86","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/00002480-197700230-00189","volume":"23","author":"N Inoue","year":"1977","unstructured":"Inoue N, Yamazaki Z, Oda T, Sugiura M, Wada T (1977) Treatment of intractable ascites by continuous reinfusion of the sterilized, cell-free and concentrated ascitic fluid. Trans Am Soc Artif Intern Organs 23:699\u2013702","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"8299_CR87","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1007\/s10147-021-01883-2","volume":"26","author":"K Ishitani","year":"2021","unstructured":"Ishitani K, Isoai A, Ito T et al (2021) Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study. Int J Clin Oncol 26:1130\u20131138. https:\/\/doi.org\/10.1007\/s10147-021-01883-2","journal-title":"Int J Clin Oncol"},{"key":"8299_CR88","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10147-011-0199-1","volume":"16","author":"K Matsusaki","year":"2011","unstructured":"Japanese CART Study Group, Matsusaki K, Ohta K, Yoshizawa A, Gyoda Y (2011) Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives. Int J Clin Oncol 16:395\u2013400. https:\/\/doi.org\/10.1007\/s10147-011-0199-1","journal-title":"Int J Clin Oncol"},{"key":"8299_CR89","unstructured":"Huaibi W, Feilong J, Zonglang L, Na S, Mingling S, Yuhong W (2017) Current status and progress of malignant ascites treatment. Journal of Critical Care in Traditional Chinese Medicine:2162\u20132164"},{"key":"8299_CR90","unstructured":"Donglai L, Pinkang W, Zhifeng Q (2008) Current status and new progress of treatment of malignant ascites with traditional Chinese and Western medicine. Chinese Journal of Integrated Traditional and Western Medicine on Digestion:137\u2013139"},{"key":"8299_CR91","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/CMAR.S100210","volume":"9","author":"M Stukan","year":"2017","unstructured":"Stukan M (2017) Drainage of malignant ascites: patient selection and perspectives. CMAR 9:115\u2013130. https:\/\/doi.org\/10.2147\/CMAR.S100210","journal-title":"CMAR"},{"key":"8299_CR92","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jpainsymman.2008.09.008","volume":"38","author":"ND Fleming","year":"2009","unstructured":"Fleming ND, Alvarez-Secord A, Von Gruenigen V, Miller MJ, Abernethy AP (2009) Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manag 38:341\u2013349. https:\/\/doi.org\/10.1016\/j.jpainsymman.2008.09.008","journal-title":"J Pain Symptom Manag"},{"key":"8299_CR93","unstructured":"Safety and effectiveness of palliative tunneled peritoneal drainage catheters in the management of refractory malignant and non-malignant ascites | SpringerLink. https:\/\/link.springer.com\/article\/10.1007\/s00270-017-1872-1. Accessed 7 Mar 2023"},{"key":"8299_CR94","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1089\/jpm.2013.0427","volume":"17","author":"G Narayanan","year":"2014","unstructured":"Narayanan G, Pezeshkmehr A, Venkat S, Guerrero G, Barbery K (2014) Safety and efficacy of the PleurX catheter for the treatment of malignant ascites. J Palliat Med 17:906\u2013912. https:\/\/doi.org\/10.1089\/jpm.2013.0427","journal-title":"J Palliat Med"},{"key":"8299_CR95","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/082585971503100406","volume":"31","author":"BCT Wong","year":"2015","unstructured":"Wong BCT, Cake L, Kachuik L, Amjadi K (2015) Indwelling peritoneal catheters for managing malignancy-associated ascites. J Palliat Care 31:243\u2013249. https:\/\/doi.org\/10.1177\/082585971503100406","journal-title":"J Palliat Care"},{"key":"8299_CR96","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.jvir.2008.09.002","volume":"19","author":"A Courtney","year":"2008","unstructured":"Courtney A, Nemcek AA, Rosenberg S, Tutton S, Darcy M, Gordon G (2008) Prospective evaluation of the PleurX catheter when used to treat recurrent ascites associated with malignancy. J Vasc Interv Radiol 19:1723\u20131731. https:\/\/doi.org\/10.1016\/j.jvir.2008.09.002","journal-title":"J Vasc Interv Radiol"},{"key":"8299_CR97","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00270-015-1258-1","volume":"39","author":"C Qu","year":"2016","unstructured":"Qu C, Xing M, Ghodadra A, McCluskey KM, Santos E, Kim HS (2016) The impact of tunneled catheters for ascites and peritoneal carcinomatosis on patient rehospitalizations. Cardiovasc Intervent Radiol 39:711\u2013716. https:\/\/doi.org\/10.1007\/s00270-015-1258-1","journal-title":"Cardiovasc Intervent Radiol"},{"key":"8299_CR98","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ijsu.2015.09.074","volume":"23","author":"SJ Valle","year":"2015","unstructured":"Valle SJ, Alzahrani NA, Alzahrani SE, Liauw W, Morris DL (2015) Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery. Int J Surg 23:176\u2013180. https:\/\/doi.org\/10.1016\/j.ijsu.2015.09.074","journal-title":"Int J Surg"},{"key":"8299_CR99","first-page":"171","volume":"40","author":"Z Zhihui","year":"2019","unstructured":"Zhihui Z, Li M (2019) Effect of Fuzi Lizhong decoction on serum tumor markers in patients with gastric cancer with spleen and kidney Yang deficiency after postoperative chemotherapy. Shaanxi Traditional Chinese Medicine 40:171\u2013173+177","journal-title":"Shaanxi Traditional Chinese Medicine"},{"key":"8299_CR100","first-page":"3112","volume":"30","author":"W Feize","year":"2015","unstructured":"Feize W, Yanni L, Liqun J (2015) Analysis of TCM syndromes of cancerous ascites. Chin J Tradit Chin Med 30:3112\u20133115","journal-title":"Chin J Tradit Chin Med"},{"key":"8299_CR101","first-page":"1254","volume":"39","author":"H Yongheng","year":"2022","unstructured":"Yongheng H, Fengjiao Z, Huixuan T, Changlin Z (2022) Clinical study on external application of Wen Tong anti-cancer recipe in the treatment of malignant ascites of advanced gastric cancer. Journal of Guangzhou University of Chinese Medicine 39:1254\u20131261","journal-title":"Journal of Guangzhou University of Chinese Medicine"},{"key":"8299_CR102","first-page":"46","volume":"50","author":"F Jiuyun","year":"2018","unstructured":"Jiuyun F, Tang Xiaojuan D, Jiajin ZD, Yong C (2018) Theoretical discussion on the treatment of malignant ascites by Warming Yang, removing blood stasis and promoting diuresis. Jiangsu Traditional Chinese Medicine 50:46\u201348","journal-title":"Jiangsu Traditional Chinese Medicine"},{"key":"8299_CR103","first-page":"841","volume":"36","author":"N Hongxing","year":"2015","unstructured":"Hongxing N (2015) Clinical observation of Zhenwu decoction in treating malignant ascites of liver cancer. Shaanxi Traditional Chinese Medicine. 36:841\u2013842","journal-title":"Shaanxi Traditional Chinese Medicine."},{"key":"#cr-split#-8299_CR104.1","unstructured":"Bin Z (2012) Clinical study on the treatment of malignant ascites by warming the spleen and kidney combined with intraperitoneal chemotherapy [internet] [Master]. Luzhou Medical College"},{"key":"#cr-split#-8299_CR104.2","unstructured":"[cited 2023 May 4]. Available from: https:\/\/kns.cnki.net\/kcms2\/article\/abstract?v=3uoqIhG8C475KOm_zrgu4lQARvep2SAkVR3-_UaYGQCi3Eil_xtLb194sgJZzRahrez5Fs7x1i11PAX7dw9_imJVfH4zbxeh&uniplatform=NZKPT"},{"key":"8299_CR105","unstructured":"Hongbing C, Liu Y, Aimin L, Min S (2002) Shipi powder for adjuvant treatment of 50 cases of malignant ascites. Shandong J Tradit Chin Med:652\u2013653"},{"key":"8299_CR106","volume-title":"Academic origin and treatment of malignant ascites in TCM","author":"Y Jinglin","year":"2016","unstructured":"Jinglin Y (2016) Academic origin and treatment of malignant ascites in TCM"},{"key":"8299_CR107","first-page":"20","volume":"36","author":"W Yitong","year":"2022","unstructured":"Yitong W, Ma Ruofan WY, Qin Z, Minghuan Z (2022) Analysis of the influencing factors of cinobufotalin injection in the treatment of malignant ascites of colon cancer. Journal of Shanghai University of Traditional Chinese Medicine 36:20\u201324","journal-title":"Journal of Shanghai University of Traditional Chinese Medicine"},{"key":"8299_CR108","first-page":"80","volume":"20","author":"Y Xiue","year":"2013","unstructured":"Xiue Y, Jinke Y (2013) Compound Kushen injection combined with chemotherapy in the treatment of 50 cases of advanced gastric cancer. China Journal of Chinese Medicine Information 20:80\u201381","journal-title":"China Journal of Chinese Medicine Information"},{"key":"8299_CR109","first-page":"28","volume":"22","author":"L Jiaqi","year":"2015","unstructured":"Jiaqi L (2015) Observation on the efficacy and safety of compound Kushen injection in the treatment of malignant ascites. China Journal of Traditional Chinese Medicine Information 22:28\u201330","journal-title":"Chin J Tradit Chin Med Information"},{"key":"8299_CR110","first-page":"5","volume":"20","author":"C Xiaochen","year":"2020","unstructured":"Xiaochen C, Xiaoming Z (2020) Randomized controlled study on the efficacy of Jianpi Lishui recipe plus hyperthermic intraperitoneal chemotherapy in improving malignant ascites. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine 20:5\u20137","journal-title":"Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08299-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08299-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08299-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T08:05:12Z","timestamp":1707725112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08299-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["8299"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08299-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"97"}}